Analysis for OS showed a trend favoring the combination that did not reach statistical significance, with a low probability of reaching statistical significance at the final analysis, anticipated in early 2022.
← all excerpts
Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction.
1
—
—